Paid Clinical Trials Providence

Discover 463 paid clinical trials in Providence, Rhode Island. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 463

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Warwick RI, Waltham MA, Methuen MA, New Hyde Park NYshow 41 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Warwick RI, Quincy MA, Newton MA, Waltham MAshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Recruiting

PHASE2

Sponsor:

Genentech, Inc.

Location:

Providence RI, Boston MA, Hartford CT, New Haven CTshow 22 more

Code:

NCT05968326

Conditions

Adenocarcinoma, Pancreatic Ductal

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autogene cevumeran

Atezolizumab

mFOLFIRINOX

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Providence RI, Warwick RI, Westerly RI, Boston MAshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Providence RI, Boston MA, Hartford CT, New Haven CTshow 103 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Providence RI, Boston MA, Farmington CT, New Haven CTshow 51 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Recruiting

PHASE1

Sponsor:

PureTech

Location:

Providence RI, Boston MA, New Brunswick NJ, Richmond VAshow 5 more

Code:

NCT05829226

Conditions

AML, Adult Recurrent

MDS

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LYT-200

Venetoclax

Azacitidine

Decitabine

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

Recruiting

PHASE3

Sponsor:

GT Medical Technologies, Inc.

Location:

Providence RI, Lebanon NH, Albany NY, Westchester NYshow 27 more

Code:

NCT04365374

Conditions

Brain Metastases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)

Stereotactic Radiation Therapy

VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency DepartmentVeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department

Recruiting

Sponsor:

Lifespan

Location:

Providence RI

Code:

NCT00468065

Conditions

Catheterization

Eligibility Criteria

Sex: All

Age: 0 - 17

Healthy Volunteers: Not accepted

Interventions

VeinViewer

Veinviewer

Impact of Sleep Duration on Immune Balance in Urban Children With AsthmaImpact of Sleep Duration on Immune Balance in Urban Children With Asthma

Recruiting

Sponsor:

Rhode Island Hospital

Location:

Providence RI

Code:

NCT05420766

Conditions

Asthma in Children

Sleep Hygiene

Sleep, Inadequate

Eligibility Criteria

Sex: All

Age: 7 - 11

Healthy Volunteers: Not accepted

Interventions

Shortened Sleep

Stabilized sleep